Long‐term Follow‐up of lntravesical Epodyl Therapy for Superficial Bladder Cancer
- 1 January 1990
- journal article
- research article
- Published by Wiley in British Journal of Urology
- Vol. 65 (1) , 32-35
- https://doi.org/10.1111/j.1464-410x.1990.tb14656.x
Abstract
The records of 111 patients with multiple superficial grade 1-2 transitional cell tumours of the bladder treated with intravesical Epodyl and followed up for a mean period of 6.4 years were retrospectively analysed. The study showed that 65% of patients responded completely after 12 weekly instillations and 46% of these remained continuously free of disease for 5 years. An initial complete response to therapy and lower pathological grade seemed to indicate a long-term successful response to treatment. In patients who failed to respond by 1 year, further therapy was of no benefit. Clearance of bladder disease by 1 year carried a 14% risk of subsequent tumour invasion by 5 years. This risk increased to 75% in those who failed to respond by 1 year.This publication has 9 references indexed in Scilit:
- INTRACAVITARY CHEMOTHERAPY FOR MULTIPLE NON-INVASIVE BLADDER TUMOURSBritish Journal of Urology, 2008
- Prognostic Factors Influencing Survival of Patients Receiving Intravesical EpodylJournal of Urology, 1982
- Intracavitary Epodyl® for Multiple, Non-Invasive, Highly Differentiated Bladder TumoursScandinavian Journal of Urology and Nephrology, 1980
- Long-term Follow-up in Patients with Superficial Bladder Tumours Treated with Intravesical EpodylBritish Journal of Urology, 1979
- Epodyl® Treatment of Bladder TumoursScandinavian Journal of Urology and Nephrology, 1979
- Epodyl in management of noninvasive vesical neoplasmsUrology, 1978
- Intravesical Epodyl in the Management of Bladder Tumors: Combined Experience of the Yorkshire Urological Cancer Research GroupJournal of Urology, 1977
- Intracavitary Chemotherapy of Diffuse Non-Infiltrating Papillary Carcinoma of the BladderJournal of Urology, 1966